The Daily Byte
Breaking
Welcome to The Daily Byte — real stories from across Pakistan.
Sunday, 22 November 2026 · Pakistan

The Daily Byte

Stories from Pakistan that deserve to be heard
Minor World

White House pulls FDA nominee Overton

By The Daily Byte ·22 Nov 2026 ·4 min read
Dr Heidi Overton, nominee to lead the FDA, speaking during her Senate confirmation hearing

The White House has abruptly withdrawn its nominee to lead the Food and Drug Administration, late on Tuesday, hours before a Senate committee was due to vote on whether to advance her.

Dr Heidi Overton, a physician and White House domestic policy adviser, was nominated in August to run the agency, which regulates medicines, food and medical devices. The Senate Health, Education, Labor and Pensions Committee had been scheduled to vote on her nomination on Wednesday morning.

The decision ends her bid after questions emerged about whether she had enough support to win confirmation. With Democrats expected to oppose her, she needed the votes of all 12 Republicans on the 21-member committee to advance to the full Senate.

A decision that blindsided health officials

The move caught senior health officials by surprise. CNN reported that Overton’s team found out about her fate from an Axios report, and that officials had believed only hours earlier that she had secured enough support to advance.

Her team had spent Tuesday afternoon negotiating concessions with Senator Josh Hawley to win what officials saw as the crucial final vote. Hours after striking that deal, the White House dropped her candidacy, angering Senator Bill Cassidy, the Louisiana Republican who chairs the health committee.

“Tonight, the White House abandoned a viable confirmation path for Dr. Overton,” Cassidy wrote on X shortly after the nomination was pulled. “I believe she would have had the votes to pass out of committee and pass the full Senate.”

People familiar with the matter told CNN that Health Secretary Robert F. Kennedy Jr. and the new White House chief of staff, Stephen Miller, had soured on Overton in the months since President Donald Trump first hailed her as a “ROCKSTAR” nominee. Trump had nominated her partly on the endorsement of his former chief of staff, Susie Wiles, and discussions about her future intensified after Wiles was replaced by Miller.

Overton had also faced questions about her role in setting White House vaccine policy. Cassidy had once called her support for breaking up combination vaccines, including the measles, mumps and rubella shot, “almost disqualifying”. He later said anti-abortion Republicans had sought commitments on “life issues” from the White House, and that “the Administration withdrew Dr. Overton rather than make such commitments.”

FDA left without a permanent leader

The withdrawal is now likely to leave the FDA without a permanent leader well into next year. The agency has been run by an acting commissioner, Kyle Diamantas, a lawyer rather than a doctor, since the previous confirmed commissioner, Dr Marty Makary, stepped down in May.

Cassidy appeared to rule out considering another nominee before Republicans lose control of the Senate in January, writing that “with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats.”

Attention has turned to who might be nominated instead. Outgoing Kansas Senator Roger Marshall, an obstetrician-gynaecologist who chairs the Senate’s Make America Healthy Again caucus, has expressed interest in the role, according to people familiar with private discussions. Sara Brenner, a physician and former FDA official, has also been mentioned as a possible replacement.

The White House did not immediately comment on its decision, or give a timeline for picking a new nominee. Officials have not ruled out a recess appointment or simply leaving an acting commissioner in place.

The administration has now pulled its first two picks to be surgeon general, Janette Nesheiwat and Casey Means, while its third choice, Nicole Saphie, awaits a full Senate vote. With so little time left in the session, the FDA looks set to enter 2027 still led by an acting chief.